Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration DOI Creative Commons
Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny

и другие.

Drugs - Real World Outcomes, Год журнала: 2024, Номер unknown

Опубликована: Сен. 13, 2024

Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management strategies to achieve functional recovery.

Язык: Английский

Residual Fatigue in Unipolar and Bipolar Depression: A Systematic Review DOI Creative Commons
Michał Pastuszak, Wiesław Jerzy Cubała, Katarzyna Jakuszkowiak‐Wojten

и другие.

Neuropsychopharmacology Reports, Год журнала: 2025, Номер 45(1)

Опубликована: Янв. 9, 2025

ABSTRACT Background Residual fatigue is a common and debilitating symptom in patients with unipolar bipolar depression, even after achieving partial or full remission. It significantly impacts patients' quality of life increases the risk relapse. This systematic review aims to evaluate prevalence effectiveness therapeutic options for residual individuals major depressive disorder (MDD) (BD). Methods A comprehensive search was conducted PubMed, SCOPUS, Web Science databases up September 2024. The protocol this registered PROSPERO. strategy included terms related depression fatigue. Studies were if they provided data on adult diagnosed MDD BD, measured treatment Risk bias assessed using Cochrane Bias tool randomized controlled trials (RCTs) Newcastle–Ottawa Scale non‐randomized studies. Results Twenty studies review. vast majority reported MDD, single papers investigated BD. by 83% patients, moderate severe affected smaller percentage. Pharmacological treatments, such as modafinil lesser extent atomoxetine, demonstrated short‐term reductions Conclusion remains significant challenge persisting large portion despite interventions like appear promising, but more research needed, especially Standardized assessment tools longer‐term are essential better understand treat Trial Registration PROSPERO identifier: CRD42024543087

Язык: Английский

Процитировано

0
Special Issue on “Ketamine, MDMA, and Psychedelics in the Treatment of Neuropsychiatric Disorders” DOI
Kenji Hashimoto,

Xingming Wang,

Jichun Zhang

и другие.

Asian Journal of Psychiatry, Год журнала: 2025, Номер 106, С. 104426 - 104426

Опубликована: Март 5, 2025

Язык: Английский

Процитировано

0
Advances in the Study of NMDA Receptors in Depression Pathogenesis and the Antidepressant Efficacy of Their Antagonists DOI
Mingrui Chen,

Jingyan Jin,

Hongsheng Bi

и другие.

Asian Journal of Psychiatry, Год журнала: 2025, Номер unknown, С. 104502 - 104502

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration DOI Creative Commons
Michał Pastuszak, Wiesław Jerzy Cubała, Aleksander Kwaśny

и другие.

Drugs - Real World Outcomes, Год журнала: 2024, Номер unknown

Опубликована: Сен. 13, 2024

Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management strategies to achieve functional recovery.

Язык: Английский

Процитировано

1